The EMA rejected a license for Alzheimer's treatment lecanemab, citing risks of brain bleeding and swelling that outweighed benefits of slowing cognitive decline by a quarter in trials.
Although the drug was approved in the US, the EMA determined that the benefits of lecanemab were not sufficient to offset the risks, especially concerning frequent amyloid-related imaging abnormalities in the brain.
[
Collection
]
[
|
...
]